Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec:5:1208-1219.
doi: 10.1200/CCI.21.00102.

Applications of Artificial Intelligence in Pediatric Oncology: A Systematic Review

Siddhi Ramesh  1 , Sukarn Chokkara  1 , Timothy Shen  1 , Ajay Major  2 , Samuel L Volchenboum  3 , Anoop Mayampurath  3 , Mark A Applebaum  3
Affiliations

Applications of Artificial Intelligence in Pediatric Oncology: A Systematic Review

Siddhi Ramesh et al. JCO Clin Cancer Inform. 2021 Dec.

Abstract

Purpose: There is a need for an improved understanding of clinical and biologic risk factors in pediatric cancer to improve patient outcomes. Machine learning (ML) represents the application of computational inference from advanced statistical methods that can be applied to increasing amount of data available for study in pediatric oncology. The goal of this systematic review was to systematically characterize the state of ML in pediatric oncology and highlight advances and opportunities in the field.

Methods: We conducted a systematic review of the Embase, Scopus, and MEDLINE databases for applications of ML in pediatric oncology. Query results from all three databases were aggregated and duplicate studies were removed.

Results: A total of 42 unique articles that examined the applications of ML in pediatric oncology met inclusion criteria for review. We identified 20 studies of CNS tumors, 13 of solid tumors, and nine of leukemia. ML tasks included classification, prediction of treatment response, and dose optimization with a variety of methods being used including neural network, k-nearest neighbor, random forest, naive Bayes, and support vector machines. Strengths of the identified studies included matching or outperforming physician comparators via automated analysis and predicting therapeutic response. Common limitations included significant heterogeneity in reporting standards, clinical applicability, small sample sizes, and missing external validation cohorts.

Conclusion: We identified areas where ML can enhance clinical care in ways that may not otherwise be achievable. Although ML promises enormous potential in improving diagnostics, decision making, and monitoring for children with cancer, the field remains in early stages and future work will be aided by standards and guidelines to ensure rigorous methodologic design and maximizing clinical utility.

PubMed Disclaimer

Conflict of interest statement

Samuel L. VolchenboumStock and Other Ownership Interests: Litmus HealthConsulting or Advisory Role: AccordantTravel, Accommodations, Expenses: Sanford Health Anoop MayampurathStock and Other Ownership Interests: Litmus Health Mark A. ApplebaumConsulting or Advisory Role: Fennec PharmaNo other potential conflicts of interest were reported.

Figures

FIG 1.
FIG 1.
Flow diagram of papers from initial abstraction through inclusion review process.
See this image and copyright information in PMC

References

    1. Davidoff AM.Pediatric oncology Semin Pediatr Surg 19225–2332010 - PMC - PubMed
    1. Frobisher C, Glaser A, Levitt GA, et al. Risk stratification of childhood cancer survivors necessary for evidence-based clinical long-term follow-up Br J Cancer 1171723–17312017 - PMC - PubMed
    1. Pui CH, Gajjar AJ, Kane JR, et al. Challenging issues in pediatric oncology Nat Rev Clin Oncol 8540–5492011 - PMC - PubMed
    1. O'Leary M, Krailo M, Anderson JR, et al. Progress in childhood cancer: 50 Years of research collaboration, a report from the Children's Oncology Group Semin Oncol 35484–4932008 - PMC - PubMed
    1. Dixon SB, Bjornard KL, Alberts NM, et al. Factors influencing risk-based care of the childhood cancer survivor in the 21st century CA Cancer J Clin 68133–1522018 - PMC - PubMed

Publication types